Printer Friendly

CYTOGEN ANNOUNCES PRODUCT DEVELOPMENT UPDATE

 PRINCETON, N.J., July 15 /PRNewswire/ -- Cytogen Corporation (NASDAQ: CYTO) updated several biotechnology analysts on the progress of its marketing and research activities during a meeting held in Princeton today.
 During the presentation, the status of various anticipated product application filings was reviewed, including estimated filing dates for two of the company's next products in the pipeline, Samarium EDTMP, for bone pain relief of cancer metastases, and OncoScint(R) Prostate, for imaging prostate cancer.
 Cytogen has taken over all late-stage clinical trials for Samarium EDTMP in the United States and Europe, as was agreed with the Dow Chemical Company. Cytogen is on schedule to file a New Drug Application in the first half of 1994 with the U.S. Food and Drug Administration for the use of this product in painful bone metastases associated with cancer.
 The filing of a Product License Application (PLA) for OncoScint Prostate, planned for year-end 1993 as a pre-surgical indication, will be held to permit the completion of a second protocol which the company believes will support a claim for the detection of occult, or undetected, disease. Martin D. Cleary, group vice president and CFO, explains, "Although the confirmation of occult disease requires a longer time commitment, the combined market opportunities represented by both indications is far greater than a presurgical indication alone." The Company is now projecting a PLA filing date for OncoScint Prostate in the second half of 1994.
 Cytogen is a biopharmaceutical company engaged in the development of products for the targeted delivery of diagnostic and therapeutic substances directly to sites of disease. Cytogen uses its patented and proprietary "linker" technology primarily to develop specific cancer diagnostic imaging and cancer therapeutic products.
 /delval/
 -0- 7/15/93
 /CONTACT: Mary Beals, director-Corporate Communications of Cytogen Corporation, 609-987-8221/
 (CYTO)


CO: Cytogen Corporation ST: New Jersey IN: MTC SU:

MJ -- PH019 -- 1931 07/15/93 12:01 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 15, 1993
Words:313
Previous Article:STANDARD & POOR'S STOCK PRICE INDEX NOON, THURSDAY, JULY 15 /PRN/
Next Article:LOCAL COMPANY RECEIVES SBIR GRANT
Topics:


Related Articles
CYTOGEN ANNOUNCES SATISFACTION WITH PRODUCT LAUNCH
/C O R R E C T I O N -- CYTOGEN/(Correction Notice)
CYTOGEN Awarded Patent on Prostate Specific Membrane Peptides.
Cytogen Updates on Product Marketing Rights in Canada.
Cytogen Announces Sale of $5 Million in Common Stock to State of Wisconsin Investment Board.
Cytogen Corporation Expands Senior Management Team.
Cytogen Corporation Adds to Senior Management Team; Dr. Nicholas Borys Appointed Vice President of Medical Affairs.
Cytogen Invites Investors to Join Its Second Quarter Conference Call on the Web.
Cytogen Announces Senior Management Promotions.
Cytogen to Introduce Next-Generation Palladium Brachytherapy Seed Implant.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters